MetaCap

ADARx Pharmaceuticals (ADRX) vs Nurix Therapeutics (NRIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ADARx Pharmaceuticals is the larger company by market cap ($1.42 billion vs $1.40 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADRX-33.90%NRIX-44.15%
+22%-13%-47%
Sep 25, 20261 yearNov 20, 2026
ADRX-33.90%NRIX-44.15%
+20%-14%-47%
Sep 21, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADRX versus NRIX key metrics
MetricADRXNRIX
Share price$12.79$12.85
Market cap$1.42B$1.40B
1-day change-9.68%-5.55%
YTD return—-32.26%
1-year return—-23.33%
5-year return—-57.25%
P/E ratio (TTM)—5.29
EPS (TTM)$-6.75$2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$83.98M
Revenue growth (YoY)—+53.95%
Net income (latest FY)—$-264.46M
Operating margin—-340.16%
Net margin—-314.90%
52-week high$23.21$28.23
52-week low$12.50$12.83
Distance from 52-week high-44.89%-54.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+167.79%+160.80%
Average volume650.63K2.47M
Shares outstanding111.19M109.25M
Employees100317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ADARx Pharmaceuticals

ADRX stock →

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Nurix Therapeutics

NRIX stock →

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

ADRX vs NRIX FAQ

Which is bigger, ADARx Pharmaceuticals or Nurix Therapeutics?

ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.42B compared with $1.40B for Nurix Therapeutics (NRIX).

Are ADARx Pharmaceuticals and Nurix Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons